Search

Displaying results 6631 - 6640 of 10000 in total
  1. Drug

    Tetracoccosporium paxianum

    go.drugbank.com/drugs/DB10849
    Approved

    Tetracoccosporium paxianum is a fungus which can provoke allergic reactions. Tetracoccosporium paxianum extract is used in allergenic testing.

    Mixtures: C Mold Mixture, C Mold Mixture
  2. Drug

    Cladosporium herbarum

    go.drugbank.com/drugs/DB10865
    Approved

    Cladosporium herbarum is a fungus which can provoke allergic reactions. Cladosporium herbarum extract is used in allergenic testing.

  3. Drug

    Chrysonilia sitophila

    go.drugbank.com/drugs/DB10935
    Approved

    Chrysonilia sitophila is a fungus which can provoke allergic reactions. Chrysonilia sitophila extract is used in allergenic testing.

  4. Drug

    Aspergillus nidulans

    go.drugbank.com/drugs/DB11022
    Approved

    Aspergillus nidulans is a fungus which can provoke allergic reactions. Aspergillus nidulans extract is used in allergenic testing.

    Mixtures: Molds - Mold Mix 4, Molds - Mold Mix 4
  5. Drug

    Dendryphiella vinosa

    go.drugbank.com/drugs/DB11025
    Approved

    Dendryphiella vinosa is a fungus which can provoke allergic reactions. Dendryphiella vinosa extract is used in allergenic testing.

  6. Drug

    Human umbilical cord blood mononuclear cell-conditioned medium

    go.drugbank.com/drugs/DB15724
    Experimental

    Thus, the media in which they are cultured is believed to also have therapeutic potential. … Transplantation with human umbilical cord blood mononuclear cells (HUCBC) has demonstrated promising results in various disease states.

  7. Drug

    LuLym-T

    go.drugbank.com/drugs/DB17405
    Experimental

    LuLym-T is an investigational autologous immune cell therapy consisting of activated T Lymphocytes. Developed by Lukas Biomedical, Inc., it is currently being investigated in hepatocellular carcinoma.

    Synonyms: LuLym-T, Autologous Activated T Lymphocytes (ATL)
  8. Drug

    Osanetant

    go.drugbank.com/drugs/DB04872
    Investigational

    In a review of its R&D portfolio, the company announced in August 2005 that it would cease any further development of osanetant. … Developed by Sanofi-Aventis (formerly Sanofi-Synthelabo), osanetant (SR-142801) is an NK3 receptor antagonist which was under development for the treatment of schizophrenia and other Central Nervous System

    Categories: Heterocyclic Compounds, 1-Ring
  9. Drug

    TAK-751S

    go.drugbank.com/drugs/DB06432
    Investigational

    TAK-751S is a synthetic analog of Shiga toxin (Stx) receptor, Gb3, produced by enterohemorrhagic _Escherichia coli_.[A260296]

  10. Drug

    Oral Polio Vaccine

    go.drugbank.com/drugs/DB15864
    Investigational

    The polio vaccine can be either administered in the inactivated form or the oral form, although both series comprises 4 doses and is also interchangeable in administration form so long all as 4 doses are … After administration, OPV strains extensively multiply in the intestinal tract, becoming widely spread in the community to immunize a sizable proportion of those unvaccinated in the population[A220163]